<DOC>
	<DOCNO>NCT00953615</DOCNO>
	<brief_summary>The purpose study determine safety benefit Thalidomide primary sclerosing cholangitis ( PSC ) . This six month study .</brief_summary>
	<brief_title>Thalidomide Treatment Primary Sclerosing Cholangitis ( PSC )</brief_title>
	<detailed_description>At entry , patient complete history physical , blood test , ultrasound , complete questionnaire . Eligible patient take Thalidomide 400 mg day even . Patients start dose 100 mg per day two week , increase 100 mg per day every two week maximum dose 400 mg per day 6 month . Patients return 6 month evaluation , blood test completion questionnaire . Blood test perform mailed-in kit 3 month . Patients receive weekly phone call first 2 month bi-monthly thereafter .</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Previous diagnosis primary sclerosing cholangitis define : serum alkaline phosphatase level great equal 1.5 time upper limit normal , negative serum antimitochondrial antibody test , cholangiography diagnostic PSC without etiology biliary obstruction , liver histology consistent diagnostic PSC Patients must give write informed consent . Patients must willing able comply recent version FDAmandated System Thalidomide Education Prescribing Safety ( S.T.E.P.S.Â® ) program . Pregnant and/or lactate female Inability unwillingness practice contraceptive measure prevention pregnancy History hypersensitivity reaction thalidomide Inability provide consent Findings suggestive liver disease etiology primary biliary cirrhosis , chronic alcoholic liver disease , chronic hepatitis B C infection , hemochromatosis , Wilson 's disease , alpha1antitrypsin deficiency , autoimmune hepatitis , cryptogenic liver disease Anticipated need liver transplantation one year decompensated chronic liver disease recurrent variceal bleeding , spontaneous hepatic encephalopathy , refractory ascites Treatment tacrolimus , cyclosporine , sirolimus , ursodeoxycholic acid , corticosteroid , colchicine , methotrexate , azathioprine , cyclosporine , chlorambucil , budesonide , pentoxifylline , nicotine , silymarin , vitamin E pirfenidone precede three month History peripheral neuropathy Use medication significant drugdrug interaction thalidomide History Human Immunodeficiency Virus ( HIV ) positive status Acquired Immunodeficiency Syndrome ( AIDS ) History coexistent advance malignancy History coexistent severe cardiovascular disease History coexistent severe renal disease History current excessive recent ( within 6 month ) alcohol use Any condition , opinion investigator , would interfere patient 's ability complete study safely successfully History thrombolytic event . Combination use corticosteroid increase risk deep vein thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>PSC</keyword>
	<keyword>Thalidomide</keyword>
</DOC>